Merrill Lynch Reconfirmed Party City Holdco (PRTY)’s “Hold” Rating; Cymabay Therapeutics, Inc. (CBAY) Covered By 6 Bullish Analysts Last Week

Among 6 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 16 analyst reports since July 21, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, October 25 report. The rating was maintained by Leerink Swann on Tuesday, November 28 with “Buy”. Cantor Fitzgerald initiated Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, September 19. Cantor Fitzgerald has “Buy” rating and $16.0 target. Piper Jaffray maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Monday, July 17. Piper Jaffray has “Buy” rating and $6.5000 target. H.C. Wainwright maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Wednesday, January 4. H.C. Wainwright has “Neutral” rating and $2.50 target. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, July 21. The stock has “Buy” rating by Piper Jaffray on Tuesday, July 25. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by H.C. Wainwright on Monday, July 17. H.C. Wainwright initiated Cymabay Therapeutics, Inc. (NASDAQ:CBAY) on Tuesday, September 8 with “Buy” rating. The firm has “Buy” rating given on Monday, September 11 by Piper Jaffray. See Cymabay Therapeutics, Inc. (NASDAQ:CBAY) latest ratings:

28/11/2017 Broker: Leerink Swann Rating: Buy New Target: $16.0 Maintain
25/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
19/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Initiate
11/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $12.0 Maintain
23/08/2017 Broker: Leerink Swann Rating: Outperform New Target: $12 Initiates Coverage On
25/07/2017 Broker: Piper Jaffray Rating: Buy New Target: $12.0000 Maintain
17/07/2017 Broker: Piper Jaffray Rating: Buy New Target: $6.5000 Maintain
17/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $12.0000 Maintain

Among 9 analysts covering Party City Holdco Inc (NYSE:PRTY), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Party City Holdco Inc has $25 highest and $14.0 lowest target. $16.56’s average target is 20.44% above currents $13.75 stock price. Party City Holdco Inc had 19 analyst reports since August 14, 2015 according to SRatingsIntel. The rating was upgraded by BMO Capital Markets on Tuesday, October 24 to “Buy”. BMO Capital Markets maintained Party City Holdco Inc. (NYSE:PRTY) on Thursday, August 3 with “Market Perform” rating. The stock has “Outperform” rating by Telsey Advisory Group on Friday, August 5. Deutsche Bank maintained Party City Holdco Inc. (NYSE:PRTY) on Friday, March 11 with “Buy” rating. Telsey Advisory Group maintained Party City Holdco Inc. (NYSE:PRTY) on Thursday, May 12 with “Outperform” rating. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, October 26. The firm has “Buy” rating by J.P. Morgan given on Monday, November 13. As per Monday, November 13, the company rating was reinitiated by JP Morgan. The stock of Party City Holdco Inc. (NYSE:PRTY) earned “Equal-Weight” rating by Morgan Stanley on Wednesday, November 8. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Tuesday, January 19 report.

The stock decreased 1.93% or $0.18 during the last trading session, reaching $9.13. About 513,000 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since December 27, 2016 and is uptrending. It has outperformed by 52.56% the S&P500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $400.48 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

The stock decreased 1.43% or $0.2 during the last trading session, reaching $13.75. About 867,308 shares traded. Party City Holdco Inc. (NYSE:PRTY) has risen 24.80% since December 27, 2016 and is uptrending. It has outperformed by 8.10% the S&P500.

Analysts await Party City Holdco Inc. (NYSE:PRTY) to report earnings on March, 8. They expect $0.77 earnings per share, up 2.67% or $0.02 from last year’s $0.75 per share. PRTY’s profit will be $74.70 million for 4.46 P/E if the $0.77 EPS becomes a reality. After $0.13 actual earnings per share reported by Party City Holdco Inc. for the previous quarter, Wall Street now forecasts 492.31% EPS growth.

Party City Holdco Inc., through its subsidiaries, designs, makes, sources, and distributes party supplies in the United States and internationally. The company has market cap of $1.33 billion. The firm operates in two divisions, Retail and Wholesale. It has a 14.35 P/E ratio. It offers paper and plastic tableware, accessories and novelties, metallic and latex balloons, Halloween and other costumes, decorations, and stationery and gift items.